Skip to main content
PMC home page
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2024 Feb 1;15:1330797. doi: 10.3389/fphar.2024.1330797

Examining the clinical relevance of metformin as an antioxidant intervention

Angelika Buczyńska 1,*, Iwona Sidorkiewicz 2, Adam Jacek Krętowski 1,3, Agnieszka Adamska 3,*
PMCID: PMC10867198  PMID: 38362157

Abstract

In physiological concentrations, reactive oxygen species play a vital role in regulating cell signaling and gene expression. Nevertheless, oxidative stress is implicated in the pathogenesis of numerous diseases and can inflict damage on diverse cell types and tissues. Thus, understanding the factors that mitigate the deleterious effects of oxidative stress is imperative for identifying new therapeutic targets. In light of the absence of direct treatment recommendations for reducing oxidative stress, there is a continuing need for fundamental research that utilizes innovative therapeutic approaches. Metformin, known for its multifaceted beneficial properties, is acknowledged for its ability to counteract the adverse effects of increased oxidative stress at both molecular and cellular levels. In this review, we delve into recent insights regarding metformin’s antioxidant attributes, aiming to expand its clinical applicability. Our review proposes that metformin holds promise as a potential adjunctive therapy for various diseases, given its modulation of oxidative stress characteristics and regulation of diverse metabolic pathways. These pathways include lipid metabolism, hormone synthesis, and immunological responses, all of which may experience dysregulation in disease states, contributing to increased oxidative stress. Furthermore, our review introduces potential novel metformin-based interventions that may merit consideration in future research. Nevertheless, the necessity for clinical trials involving this drug remains imperative, as they are essential for establishing therapeutic dosages and addressing challenges associated with dose-dependent effects.

Keywords: metformin, oxidative stress, antioxidant intervention, oxidative status, novel treatment

1 Introduction

The hypoglycemic activity of metformin (a synthetic derivative of guanidine) was first described in 1968. Since its approval by the U.S. Food and Drug Administration (FDA) in 1994, metformin has become a first-line treatment for type 2 diabetes mellitus (T2DM) (Clarke and Duncan, 1968; Corcoran and Jacobs, 2021). Nowadays, metformin has also been approved for several non-FDA-approved indications, including gestational diabetes, management of antipsychotic-induced weight gain, and treatment of polycystic ovary syndrome (PCOS) (Dutta et al., 2001; Sirmans and Pate, 2014; Corcoran and Jacobs, 2021). Beyond its well-established antihyperglycemic impact, metformin demonstrates anti-inflammatory and antioxidant activities, contributing to its potential benefits in conditions associated with inflammation and oxidative stress (Bharath and Nikolajczyk, 2021). Notably, metformin is linked to cardioprotective effects, modest weight loss, and potential anticancer properties (Mallik and Chowdhury, 2018). It is also being explored for neuroprotective effects and its role in promoting healthy aging (Foretz et al., 2023). Additionally, metformin may influence gut microbiota, further implicating its broad impact on various physiological processes (Triggle et al., 2022). While these pleiotropic effects hold promise for additional therapeutic use of metformin, ongoing research is crucial to fully understand the underlying mechanisms and determine their clinical significance in diverse medical conditions (Anedda et al., 2008; Diniz Vilela et al., 2016; Forman and Zhang, 2021). Recent studies involving newly diagnosed T2DM patients subjected to a 12-month observation period during metformin intervention have elucidated that metformin usage proves more efficacious in attenuating oxidative stress when compared to lifestyle modification alone. Additionally, within this observational timeframe, individuals undergoing metformin intervention manifested notable reductions in concentrations of advanced oxidation protein products (AOPP) and advanced glycation end products (AGE) in comparison to the control group (Mirmiranpour et al., 2013). According to study conducted by Adeshara et al., augmented antioxidant properties were evident following a 3-month period of metformin administration in patients with T2DM patients (Adeshara et al., 2020). Given the existing inconsistencies in the results of contemporary studies, a thorough review of fundamental scientific investigations is imperative to assess the antioxidant properties of metformin accurately. The current lack of consensus in findings underscores the necessity for a meticulous examination using basic science studies. This review aims to synthesize and analyze the diverse outcomes reported in these studies, thereby providing a comprehensive perspective on the potential antioxidative effects of metformin. Through a detailed scrutiny of underlying molecular mechanisms and variations in experimental methodologies, this review aspires to contribute substantively to the elucidation of metformin’s role as an antioxidant.

2 Materials and methods

The literature review was conducted using various databases including Scopus, Web of Science, PubMed, Directory of Open Access Journals (DOAJ), ClinicalTrials.gov, and Science Direct. The literature search was conducted using relevant keywords such as “metformin intervention," “oxidative stress," “antioxidant capacity," and “antioxidation." Exclusion criteria for the review included incorrect formulated conclusions, inaccurate study group plurality, unclear criteria for patient inclusion/exclusion, and inconsistent research methodology. The review protocol was registered in the PROSPERO database (CRD42022299568). Thus, all PROSPERO guidelines were incorporated during the execution of the literature review (Schiavo, 2019).

3 Multifaceted effects of metformin: understanding its pleiotropic properties

Metformin provides hypoglycemic effect through various mechanisms, such as inhibition of gluconeogenesis in the liver, increased glucose uptake in skeletal muscle and hepatocytes, decreased glucose absorption in the gastrointestinal tract (Viollet et al., 2012; McCreight et al., 2016; Lv and Guo, 2020). The metformin intervention also plays a role in glycerol-3-phosphate dehydrogenase and selectively inhibits the substrate (glycerol and lactate) involved in hepatic gluconeogenesis (Lamoia and Shulman, 2021). Its intervention is also associated with the transcriptional regulation of hepatic gluconeogenesis through antagonization of hepatic glucagon signaling. This mechanism involves reducing cyclic adenosine monophosphate (AMP) accumulation and preventing CREB-mediated transcription of gluconeogenic genes, leading to reduced glucose 6-phosphatase (G6pc) and phosphoenolpyruvate carboxykinase 1 (Pck1) expression (He et al., 2009; Miller et al., 2013; Johanns et al., 2016). Metformin indirectly regulates hepatic gluconeogenesis by controlling glycerol delivery to the liver through white adipose tissue (WAT) lipolysis. In this process, glycerol is phosphorylated and converted to dihydroxyacetone phosphate (DHAP) by mitochondrial glycerol-3-phosphate dehydrogenase (GPD2) in a redox-dependent manner. Studies on rodents by Madiraju et al. showed that metformin treatment increased plasma glycerol and decreased hepatic glycerol-3-phosphate (G3P) activity, indicating reduced gluconeogenesis (Madiraju et al., 2014; Madiraju et al., 2018). Furthermore, metformin enhances this process by promoting an increase in the secretion of glucagon-like peptide 1 (GLP-1). GLP-1 is a hormone that plays a crucial role in regulating blood glucose levels and insulin secretion. By augmenting GLP-1 secretion, metformin contributes to the improvement of glucose metabolism and insulin sensitivity, which are vital factors in managing conditions such as T2DM. This combined effect of metformin on glycerol-3-phosphate dehydrogenase, substrate inhibition, and GLP-1 secretion makes it an essential therapeutic option for controlling hepatic gluconeogenesis and maintaining glucose homeostasis in individuals with insulin resistance or T2DM (Bahne et al., 2018). In addition to its other beneficial effects, metformin also enhances tissue sensitivity to insulin through an increase in the activity of the insulin receptor tyrosine kinase. The insulin receptor is a transmembrane protein found on the surface of target cells, and its activation is a critical step in insulin signaling. When insulin binds to its receptor, it triggers a series of molecular events, leading to the activation of the insulin receptor tyrosine kinase. This kinase then adds phosphate groups to specific tyrosine residues on the insulin receptor and other intracellular substrates, initiating a cascade of signaling pathways that promote glucose uptake, glycogen synthesis, and other insulin-dependent cellular responses (He et al., 2009). Metformin’s ability to boost the activity of insulin receptor tyrosine kinase enhances the responsiveness of cells to insulin’s actions. As a result, tissues become more receptive to glucose uptake and utilization, which is particularly beneficial in individuals with insulin resistance or T2DM. By improving insulin sensitivity and glucose utilization in tissues, metformin plays a crucial role in managing blood glucose levels (Mulherin et al., 2011).

Apart from its hypoglycemic effects, metformin has been shown to have several other beneficial effects on lipid profile, immune and coagulation responses, and hormone synthesis (Akinci et al., 2008; Buczyńska et al., 2022). This is due to the activation of AMPK, which regulates many metabolic pathways (Musi et al., 2002; Vancura et al., 2018; Meyer et al., 2020). Sterol regulatory element binding proteins (SREBP), which regulates the expression of genes involved in lipogenesis, is also positively regulated by insulin and negatively regulated by AMPK activity in the intestine (Musi et al., 2002). Metformin has been shown to decrease the synthesis of intestine-derived triglycerides-rich lipoproteins, which leads to a decrease in plasma concentrations of chylomicrons and chylomicron remnant lipoprotein fractions (Zhang et al., 2018). This is achieved by a decrease in the expression of SREBP-1c, SREBP-2, ACC1, and Apo A-IV (van Stee et al., 2018; Vancura et al., 2018; Zhang et al., 2018; Jia et al., 2019; Buczyńska et al., 2020; Meyer et al., 2020). Metformin also enhances the fluidity of cell membranes (Marc et al., 2014) and inhibits the inflammatory process by increasing plasma fibrinolytic activity, reducing the concentration of plasminogen activator inhibitor-1 (PAI-1), preventing excessive activation of platelets, and reducing endothelial damage (Hirsch et al., 2013; Bai and Chen, 2021), and these properties were proven during clinical trials among T2DM and metabolic syndrome patients.

Metformin also has a significant impact on the PCOS, decreasing luteinizing hormone and androgen synthesis, resulting in normalizing the menstruation cycle (Vause et al., 2010; Shao et al., 2014). Metformin treatment was associated with a decrease in the levels of serum thyroid-stimulating hormone (TSH) in diabetic patients possibly by enhancing the effects of thyroid hormones in the pituitary and activating the adenosine monophosphate-activated protein kinase (AMPK) (Meng et al., 2017). Furthermore, metformin treatment has been found to be associated with a decrease in cell proliferation and a reduction in the secretion of growth hormone (GH) (An et al., 2017). Additionally, metformin has been shown to regulate the pulsatile release of cortisol and allopregnanolone (Genazzani et al., 2009). These effects are of significant interest as dysregulation of cell proliferation, GH secretion, and cortisol levels can have implications for various health conditions, including metabolic disorders and hormonal imbalances.

The pleiotropic effects of metformin are achieved through its ability to modulate multiple factors at the molecular level. AMPK serves as a central regulator, influencing downstream targets such as eukaryotic translation initiation factor 4E-binding protein 1 (eIF-4E-BP1), glutathione peroxidase 7 (GPx7), mechanistic target of rapamycin (mTOR), nuclear factor erythroid 2-related factor 2 (Nrf2), and nuclear factor-kappa B (NF-kB). AMPK activation by metformin impacts diverse cellular processes, including translation initiation, antioxidant defense, nutrient sensing, and inflammatory responses. Additionally, metformin’s influence on nitric oxide (NO) production, poly (ADP-ribose) polymerase 1 (PARP-1) inhibition, and modulation of reactive oxygen species (ROS) and sulfur species further contributes to its multifaceted actions. The integration of these molecular mechanisms, orchestrated by AMPK, underscores metformin’s comprehensive therapeutic benefits beyond glycemic control, encompassing anti-inflammatory, antioxidant, and cytoprotective effects (Figure 1).

FIGURE 1.

FIGURE 1

Open in a new tab

Pleiotropic metformin properties.

AMPK: AMP-activated protein kinase; elif-4E-BP1: Eukaryotic translation initiation factor 4E-binding protein 1; GPx7: Glutathione peroxidase 7; mTOR: Mechanistic target of rapamycin; Nrf2: Nuclear factor erythroid 2-related factor 2; NK-kB: Nuclear factor-kappa B; NO: Nitric oxide; PARP-1: Poly (ADP-ribose) polymerase 1; PRDX-2: Peroxiredoxin-2; ROS: Reactive oxygen species; rsPG: Reactive sulfur species; SGK: Serum and glucocorticoid-regulated kinase; SIRT3: Sirtuin 3; SKN-1: Skinhead-1; STAT3: Signal transducer and activator of transcription 3; ULK1: Unc-51 like autophagy activating kinase 1.

While metformin has been demonstrated to improve mitochondrial respiration, it is worth noting that higher doses of metformin have been associated with a contrary effect, namely, reduced mitochondrial respiration. This reduction in mitochondrial respiration is attributed to metformin’s ability to decrease adenine nucleotide levels. Mitochondria are essential cellular organelles responsible for generating energy in the form of adenosine triphosphate (ATP) through oxidative phosphorylation. Metformin has been recognized for its positive impact on mitochondrial function by enhancing respiratory chain activity and promoting efficient ATP production, which is beneficial for cellular energy metabolism. However, at higher doses, metformin has been found to interfere with the levels of adenine nucleotides, including adenosine diphosphate (ADP) and ATP. Lower ADP levels can inhibit mitochondrial respiration and subsequently lead to a reduction in ATP synthesis. The dose-dependent effects of metformin on mitochondrial function underscore the importance of careful dosage management in clinical settings (Luengo et al., 2014). Additionally, metformin inhibits complex I-dependent respiration and mitochondrial glycerophosphate dehydrogenase (mGPDH) and activates sirtuin 1 (SIRT1) and sirtuin 3 (SIRT3), making it directly involved in oxidative stress modulation (Andrzejewski et al., 2014). The mechanism by which metformin may increase oxidative stress in certain circumstances involves several factors. While metformin is generally known for its beneficial effects in reducing oxidative stress and improving cellular metabolism, there are specific situations where it appears to have the opposite effect. In white adipose tissue collected from patients with T2DM or in certain experimental conditions using H4II rat hepatocellular carcinoma, metformin has been observed to induce oxidative stress. This paradoxical effect could be attributed to mitochondrial dysfunction, complex cellular interactions (the balance between antioxidant defenses and ROS generation might shift towards increased oxidative stress due to specific metabolic or signaling alterations induced by metformin), cellular adaptation (the response to metformin might differ depending on their metabolic state and the presence of pre-existing conditions) or genetic variability (individual genetic variations can influence metformin’s effects on oxidative stress) (Anedda et al., 2008).

Furthermore, it is important to note that the effectiveness of metformin varies depending on the specific tissue and the dosage used (Kefas et al., 2004; Klein et al., 2004). Different tissues may respond differently to metformin treatment, and the optimal dosage may vary for different individuals or medical conditions. Understanding the tissue-specific effects and the appropriate dosing regimens is crucial for maximizing the therapeutic benefits of metformin while minimizing potential adverse effects. Metformin has an oral bioavailability of approximately 50%, and after intestinal absorption, it accumulates in the liver (Ouslimani et al., 2005). As metformin continues to be a widely prescribed medication for conditions such as T2DM, PCOS, and metabolic syndrome, further research is warranted to explore its tissue-specific actions and refine the dosing strategies. Such insights will help optimize the use of metformin as a therapeutic intervention for various health conditions and pave the way for personalized treatment approaches in the future. Therefore, further research is still needed to determine the dose and dose-dependent modulation of oxidative stress by metformin. It is possible that metformin may increase antioxidant protection at low and medium doses, while high doses may intensify oxidative stress.

4 Unraveling the mechanisms behind metformin's antioxidant properties

Metformin can modulate oxidative stress by inhibiting ROS production through pleiotropic actions, including AMPK modulation, mitochondrial complex I inhibition, and increased antioxidant enzyme activity. This may limit the degradation of biological components, such as proteins, DNA and lipids, crucial for membrane integrity, as indicated by markers such as 8-Hydroxy-2′-deoxyguanosine (8-OHDG), AMPK activation, and modulation of several other key factors. Its influence on 8-OHDG suggests a potential in reducing oxidative DNA damage, showcasing a protective role against reactive oxygen species (ROS)-induced harm. The primary mechanism of metformin involves the activation of AMPK, enhancing cellular energy homeostasis and metabolic function. Additionally, interactions with copper ions (Cu2+) and modulation of transcription factor FOXO3 contribute to its antioxidant properties. Metformin mitigates lipid peroxidation, as evidenced by reduced levels of malondialdehyde (MDA), highlighting protection against oxidative stress-induced lipid damage. Through its impact on NADPH metabolism and reduction of ROS production, metformin plays a crucial role in maintaining cellular redox balance and defending against oxidative stress. Overall, metformin’s properties extend beyond glycemic control, encompassing antioxidative and cellular protective effects that contribute to its therapeutic benefits (Figure 2) (Samsuri et al., 2017; Bharath and Nikolajczyk, 2021; Liu et al., 2021; Buczyńska et al., 2022; Triggle et al., 2022; Foretz et al., 2023).

FIGURE 2.

FIGURE 2

Open in a new tab

Metformin antioxidant properties.

8-OHDG: 8-Hydroxy-2′-deoxyguanosine; AMPK: 5′AMP-activated protein kinase; ATP: Adenosine Triphosphate; Cu2+: Copper (II) ion; FOXO3; Forkhead box O3; LPO: Lipid Peroxidation; MDA: Malondialdehyde; NADPH: Nicotinamide Adenine Dinucleotide Phosphate; ROS: Reactive Oxygen Species.

4.1 In vitro experiments

In a study conducted by An et al., using human umbilical vein endothelial cells, it was found that metformin’s antioxidant properties, at a dose of 2 mmol/L, were achieved through specific mechanisms. The results indicated that metformin activated guanosine 5′-triphosphate cyclohydrolase 1 (GTPCH1), leading to the recoupling of endothelial nitric oxide synthase (eNOS). This recoupling of eNOS resulted in increased production of nitric oxide, which possesses antioxidant properties. Moreover, metformin inhibited nicotinamide adenine dinucleotide phosphate (NADPH) oxidase via an AMP-activated protein kinase (AMPK)-dependent pathway. NADPH oxidase is a key enzyme responsible for producing reactive oxygen species (ROS) that contribute to oxidative stress. By inhibiting NADPH oxidase, metformin helps to reduce the generation of harmful ROS, further contributing to its antioxidant effects (An et al., 2016). In a study conducted by Hou et al., the effect of metformin intervention (dose: 250 µM) on reducing reactive oxygen species (ROS) concentration in human aortic endothelial cells was investigated. The decrease in ROS levels was attributed to an increase in the concentration of the antioxidant thioredoxin (Trx). Furthermore, Trx was found to upregulate the expression of the forkhead transcription factor 3 (FOXO3) through the AMPK pathway. FOXO3 is a transcription factor that plays a role in regulating genes involved in cellular stress response and antioxidant defense. These results suggest that metformin exerts its antioxidant effects through the modulation of Trx and the subsequent activation of the AMPK-FOXO3 pathway, providing a mechanistic understanding of metformin’s antioxidative properties in human endothelial cells (Hou et al., 2010). On the contrary, Cheng et al. demonstrated that the reduction in oxidative stress induced by metformin (dose: 1 mM) is associated with the downregulation of NADPH Oxidase 4 (NOX4) expression. NOX4 is an enzyme responsible for producing reactive oxygen species (ROS) that contribute to oxidative stress in cells. The downregulation of NOX4 by metformin helps to decrease the generation of harmful ROS, providing an alternative mechanism for metformin’s antioxidative effects. These findings offer valuable insights into the diverse ways in which metformin can modulate oxidative stress in different cellular contexts (Cheng and Lanza-Jacoby, 2015). Furthermore, in a study by Ouslimani et al., where aortic endothelial cells were subjected to metformin intervention (dose: 1–5 μmol/L), it was observed that this treatment led to a reduction in intracellular reactive oxygen species (ROS) production. This effect was achieved through the regulation of NADPH oxidase activity. NADPH oxidase is an enzyme responsible for generating ROS, and metformin’s ability to modulate its activity contributed to the decrease in ROS levels, highlighting another mechanism by which metformin exerts its antioxidative properties in aortic endothelial cells (Ouslimani et al., 2005). In a study conducted by Bałdak et al., peripheral blood mononuclear human cells obtained from 10 healthy individuals were cultured with metformin (dose: 2 µM) for 24 h. The results showed a decrease in the expression of NADPH oxidase, an enzyme responsible for generating reactive oxygen species, indicating a reduction in oxidative stress. Furthermore, the metformin treatment led to an increase in the expression of various antioxidative enzymes, including superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx). These enzymes play crucial roles in neutralizing ROS and protecting cells from oxidative damage. The study suggests that metformin’s antioxidative effects in human blood cells involve downregulating NADPH oxidase and upregulating key antioxidative enzymes, which may contribute to its potential therapeutic benefits in managing oxidative stress-related conditions (Bułdak et al., 2016).

From the other hand, Anedda et al. examined metformin’s impact on white adipocytes and its influence on uncoupling protein 2 (UCP2) levels. The UCPs are transporters that decrease the efficiency of mitochondrial oxidative phosphorylation. UCP2 is believed to provide protection against oxidative stress, although alternatively, it may function in dissipating energy. Cultured rat adipocytes treated with metformin (dose: 4 mM) showed increased UCP2 and ROS levels, and decreased aconitase activity. Variations in UCP2 levels parallel ROS changes. Metformin increases lipolysis in cells, but only post-reduction in ROS and UCP2 levels. UCP2 appears unnecessary for fatty acid oxidation facilitation. Metformin treatment elevates UCP2 in white adipose tissue. In summary, metformin induces UCP2 overexpression in adipocytes, potentially minimizing oxidative stress due to drug-induced respiratory inhibition (Anedda et al., 2008). Similar results were obtained by Park et al., where increased ROS synthesis was also observed following metformin exposure using H4II rat hepatocellular carcinoma cells (Park, 2019). Treatment with metformin (dose: 5 mM) stimulated glucose consumption and lactate production, indicating an acceleration of glycolysis. Unexpectedly, metformin markedly increased ROS production. Inhibition of glycolysis by 2-deoxyglucose enhanced metformin’s pro-apoptotic effect, while the antioxidant N-acetylcysteine (NAC) suppressed all pro-apoptotic changes and ROS generation induced by metformin. These findings suggest that metformin promotes apoptosis not by interfering with glycolysis but by enhancing oxidative stress. All studies were summarized in (Table 1).

TABLE 1.

In Vitro studies evaluating the antioxidant action of metformin.

Model Dose Parameters Results References Limitations
human umbilical vein endothelial cells 2 mmol/L increased production of nitric oxide activated guanosine 5′-triphosphate cyclohydrolase 1 An et al. (2016) Alteration in eNOS Activity (alteration in the activity of eNOS in response to FG)
decreased reactive oxygen species production recoupling of endothelial nitric oxide synthase Despite the upregulation of phosphorylated eNOS, there are simultaneous changes in the generation of ROS and the production of nitric oxide (NO) under the influence of FG, eNOS becomes uncoupled. Instead of performing its normal role as an enzyme producing NO, eNOS is converted into a molecule that generates superoxide, which is a type of ROS
inhibited nicotinamide adenine dinucleotide phosphate via an AMP-activated protein kinase
human aortic endothelial cells 250 µM reducing reactive oxygen species production, increase in the concentration of the antioxidant thioredoxin upregulate the expression of the forkhead transcription factor 3 through the AMPK pathway Hou et al. (2010) various types of FOXOs may have different, and even
opposite, effects on ROS level
human endothelial cells 1 mM reducing reactive oxygen species production downregulation of NADPH Oxidase 4 activity Cheng and Lanza-Jacoby (2015) NA
aortic endothelial cells 1–5 μmol/L reducing reactive oxygen species production regulation of NADPH oxidase activity Ouslimani et al. (2005) Lack in chelation of intracellular metal ions by Metformin assessment; a contact of cells with culture medium free of metformin for 1 h or 2 h before the experiments
peripheral blood mononuclear human cells 2 µM Increased of superoxide dismutase, catalase, and glutathione peroxidase activity, reducing reactive oxygen species production decrease in the expression of NADPH oxidase upregulating key antioxidative enzymes Bułdak et al. (2016) Metformin exerts a mild effect on catalase expression, statistically small sample size, a predominant effect of metformin on the catalytic activity of the catalase enzyme
rat adipocytes 4 mM increased UCP2 levels UCP adipocytes pathway Anedda et al. (2008) The upregulation of UCP2 induced by leptin, when lipolysis and β-oxidation are also promoted, could indicate that there are all involved in energy dissipation (misleading results); polymorphisms in the human UCP2
increase of ROS
decrease in aconitase activity
H4II rat hepatocellular carcinoma cells 5 mM Increase in ROS Apoptosis induction in cancer cells Park (2019) unclear by which pathway metformin
Decrease in NAC induces ROS generation
Open in a new tab

FG, fluctuating glucose; NA, not applicable; NAC, N-acetylcysteine; NADPH, nicotinamide adenine dinucleotide phosphate; UCP2, uncoupling proteins; ROS, reactive oxygen species.

Since in vivo and in vitro studies are inconsistent, broader and more detailed studies focused on the mechanisms responsible for oxidative stress modulation under metformin intervention are still needed (Liu et al., 2021).

4.2 In vivo studies

In a study by Javadipour et al., a rat model of arsenic-induced diabetes was treated with metformin (dose: 300 mg/kg). The results showed that metformin treatment led to a reduction in oxidative stress in rat pancreatic mitochondria. This effect was achieved through the activation of the SIRT3-related metabolic pathway. SIRT3 is a mitochondrial protein known for its role in regulating cellular metabolism and maintaining mitochondrial function. Activation of the SIRT3 pathway by metformin contributed to the reduction of oxidative stress in the pancreatic mitochondria of the rats with arsenic-induced diabetes. These findings highlight the potential antioxidative effects of metformin via the SIRT3-related metabolic pathway in the context of diabetes induced by arsenic exposure. Further research in this area may provide valuable insights into the therapeutic implications of metformin for managing oxidative stress-related conditions associated with diabetes (Javadipour et al., 2019). In a study conducted by Roxo et al., using a diabetic mouse model, metformin intervention (dose: 250 mg/kg) resulted in notable improvements in lipid metabolism and a reduction in oxidative stress. The beneficial effects were achieved through the restoration of paraoxonase activity. Paraoxonase is an enzyme known for its antioxidant properties and plays a crucial role in protecting cells from oxidative damage. The study demonstrated that metformin treatment enhanced paraoxonase activity, thereby ameliorating oxidative stress in the diabetic mice. The findings from this study provide valuable insights into the mechanisms by which metformin exerts its antioxidative effects and its potential benefits in managing lipid metabolism and oxidative stress in diabetes (Roxo et al., 2019). Moreover, in a study conducted by Lai et al. using a rat model, metformin intervention (dose: 1 mmol/L) was found to be linked to a reduction in oxidative stress. This effect was achieved through the activation of the SIRT3 and AMPK pathways. These findings provide important insights into the antioxidative mechanisms of metformin through the involvement of SIRT3 and AMPK pathways, supporting its potential therapeutic benefits in managing oxidative stress-related conditions (Lai et al., 2016). In the following study Dare et al. investigated the protective effects of ergothioneine (L-egt), a recently FDA-approved bioactive compound, alone or in combination with metformin, on renal damage in a T2DM rat model. The administration of L-egt, either alone or in combination with metformin (dose: 500 mg/kg), reduced hyperglycemia and improved therapeutic outcomes via activation of nuclear factor E2-related factor 2 pathway. Thus, the treatment significantly increased the expression of major antioxidant transcription factors and cytoprotective genes, while decreasing the expression of inflammatory genes in the kidney. The combination of L-egt and metformin related to downregulation of NF-kB/TGF-β1 mRNA expression may enhance therapeutic efficacy and serve as an adjuvant therapy to alleviate renal damage in T2DM (Dare et al., 2021). All studies were summarized in Table 2 (Table 2).

TABLE 2.

The metformin antioxidant properties based on animal model studies.

Model Dose Parameters Results References Limitations
rat model of arsenic-induced diabetes 300 mg/kg reduction in oxidative stress SIRT3 pathway activation Javadipour et al. (2019) SIRT3 expression elevated parallel to other antioxidant defense component
diabetic mouse model 250 mg/kg improvements in lipid metabolism and a reduction in oxidative stress Increased paraoxonase activity Roxo et al. (2019) Uncreated metabolic memory associated with diabetes
Rat model 1 mmol/L Reduction in oxidative stress activation of the SIRT3 and AMPK pathways Lai et al. (2016) the lack of beneficial effects of nitrite and metformin in the more severely affected and older rats
Diabetic rat model 500 mg/kg metformin and L-ergothioneine significantly increased the expression of major antioxidant transcription factors and cytoprotective genes Activation of Nrf2 antioxidant Dare et al. (2021) experimental phase, no evidence for only metformin beneficial properties, combined therapy may leads to cardiac injury
Open in a new tab

AMPK, 5′AMP-activated protein kinase; Nrf2, Nuclear factor E2-related factor 2; SIRT3, sirtuin 3.

5 Metformin as an antioxidant in clinical trials: advancement in novel approaches

To date, 45 clinical trials evaluating metformin’s antioxidant properties have been registered, with 13 already completed. The most frequently evaluated population in these trials are patients with T2DM. Results from randomized clinical trials have shown that daily intake of 1000 mg of metformin among 50 patients, for 3 months can alleviate oxidative stress and restore antioxidant capacity in newly diagnosed T2DM patients (Mirmiranpour et al., 2013). Similar outcomes were obtained in the study by Pavlovic et al., where metformin intervention resulted in a reduction in erythrocyte and plasma malondialdehyde (MDA) levels and an increase in the erythrocyte activities of Cu, Zn, SOD, CAT, and glutathione levels among newly diagnosed T2DM patients (Pavlovic et al., 2000). These studies' assumptions were expanded in the study conducted by Esteghamati et al., where 99 newly diagnosed T2DM patients were divided into two groups - one undergoing metformin intervention (1,000 mg daily for 12 weeks) and the other undergoing only lifestyle modification. This study revealed that metformin intervention is associated with a greater reduction in the concentrations of advanced oxidation protein products and advanced glycation end products than lifestyle modification alone (Esteghamati et al., 2013). In the following study performed by Chakraborty et al., the effect of metformin on various stress and inflammatory-related parameters in diabetic subjects was evaluated. During the study, 208 T2DM patients were randomly assigned to the metformin and placebo groups, where metformin was supplemented at a daily dose of 2000 mg. The results showed that metformin intervention is associated with a decrease in body mass index (BMI), glycated haemoglobin (HbA1C), low density lipoprotein (LDL) levels, as well as with the reduction in the concentration of oxidative modified advanced protein products and ROS generation (Chakraborty et al., 2011). In the study conducted by Schauer et al., the effect of metformin on vascular and mitochondrial activity was evaluated in patients with type 1 diabetes, considering the origin of increased oxidative stress status. During 6 weeks of metformin intervention (dose: 1,000 mg/daily), mitochondrial complex I, II, III, V, high-sensitive C-reactive protein (hsCRP), glucagon, glycerol and vascular markers, such as endothelin-1 were measured. The study revealed that metformin intervention was associated with an increase in mitochondrial complex protein concentrations, glucagon, glycerol, and endothelin-1 levels, and a decrease in hsCRP concentration. Based on the results obtained, it can be concluded that metformin intervention has a modulatory effect on the oxidative status, but it is not characterized by direct cardiovascular prevention (Abolarin and Schauer, 2024). This means that although metformin influenced various factors related to oxidative stress and vascular activity, its use did not show a direct cardiovascular preventive effect in the context of type 1 diabetes in this particular study.

On the contrary, the study conducted by Diaz-Moralez et al. did not find evidence of metformin’s antioxidant properties. The research involved 72 patients with T2DM, out of which 41 received metformin at a dose of 1700 mg per day for at least 12 months, while 40 age- and sex-matched individuals served as control subjects. Throughout the study, ROS concentration, as well as SOD1 and CAT activities, were monitored for a year, but no significant changes were observed. The study’s results suggest that, in this specific cohort of T2DM patients, metformin did not lead to a notable reduction in ROS concentration or alterations in the activities of SOD1 and CAT, which are key antioxidant enzymes. Thus, it is essential to consider that various factors, including patient characteristics, disease progression, and treatment duration, might influence the antioxidative effects of metformin (Diaz-Morales et al., 2017).

The main ongoing clinical trials based on metformin intervention evaluating antioxidant properties were collected in Table 3 (Table 3).

TABLE 3.

Ongoing metformin based clinical trials evaluating antioxidant metformin properties.

Title Number Dose Outcome measure Measure description Time frame
Independent and Additive Effects Of Micronutrients With Metformin In Patients With PCOS NCT05653895 1000 mg daily Insulin Resistance PCOS associated insulin resistance and hyperinsulinemia by HOMA-IR 6 months
Menstural Irregularities Oligo/Anovulation, Questionnaire based history taking of each participant
Anti Mullerian Hormone Measurement of Anti mullerian hormone by ELISA
Dehydroepiandrosterone Measurement of Dehydroepiandrosterone using ELISA
Antioxidant Assays perceived stress response (PSS-14) questionnaire Measurement of Total AntiOxidant Capacity by FRAP ASSAY
Measurement MDA by TBARS
Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients NCT05298670 1,000 mg twice daily Change in IL17 in both arms as measured by ELISA. Anti-inflammatory marker After 6 months
Percentage of Quality of Life deterioration in both arms measured by MSQOL-54 Assessment of quality of life for patients, The highest and lowest values refer to the satisfaction degree of patients
Change in IL22 in both arms as measured by ELISA. Anti-inflammatory marker
Malondialdehyde in both arms as measured by Colorimetric tests Antioxidative marker
Efficacy of Injectable Vitamin D Supplementation in Females With Polycystic Ovary Syndrome NCT06045351 750 mg once at dinner for 15 days then twice daily Hyperandrogenism insulin Resistance hyperandrogenism by Free Androgen Index via Total Testosterone, Steroid Hormone Binding Globulin 24 weeks
oxidative stress HOMA-IR (serum Insulin, Fasting Blood Glucose)
Total Antioxidant Capacity
Therapeutic Intervention of Eriomin Associated With Metformin in the Control of Hyperglycemia in Pre-Diabetic Patients (Eriomin + Met) NCT06005142 1000 mg daily Fasting Glycemia Dosages of glycemia concentration (mg/dL) before and after intervention with Eriomin/placebo
OGTT Glycemia Changes in blood glucose 2 h after the OGTT (mg/dL) before and after intervention with Eriomin/placebo
HBA1C Dosages of HBA1C (%) in the blood serum/plasma before and after intervention with Eriomin/placebo
Insulin Dosages of Insulin (µU/mL) in the blood serum/plasma before and after intervention with Eriomin/placebo
Blood Lipids profile
Antioxidant Capacity Dosages of cholesterol (mg/dL), HDL-cholesterol (mg/dL) and triglycerides (mg/dL) in the blood serum/plasma before and after intervention with Eriomin/placebo
Lipid Peroxidation Dosages of TEAC (μM) in the blood serum/plasma before and after intervention with Eriomin/placebo
Dosages of MDA (mM) the blood serum/plasma before and after intervention with Eriomin/placebo
Open in a new tab

ELISA, Enzyme-Linked Immunosorbent Assay; FRAP ASSAY, ferric reducing ability of plasma assay; HBA1C, glycated hemoglobin; HDL, High-Density Lipoprotein; HOMA-IR, homeostatic model assessment for insulin resistance; IL17, Interleukin 17; IL22, Interleukin MDA, malondialdehyde; mg, milligram; MSQOL-54, Multiple Sclerosis Quality of Life-54; NCT, ClinicalTrials.gov Identifier; OGTT, oral glucose tolerance test; PCOS, polycystic ovary syndrome; TEAC, trolox equivalent antioxidant capacity; TBARS, thiobarbituric acid reactive substances.

6 The future of antioxidant treatment discussion: considerations and opportunities for metformin intervention

Since oxidative stress is involved in the pathogenesis of many diseases, it is crucial to find ways to overcome its negative impact (Blacker and Duchen, 2016; Buczyńska et al., 2021a; Adamska et al., 2021; Buczyńska et al., 2021b; Buczyńska et al., 2023a; Buczyńska et al., 2023b; Buczyńska et al., 2023c; Kościuszko et al., 2023). This review focused on presenting new and promising mechanisms responsible for the potential antioxidant use of metformin, while forecasting further research directions (Salvatore et al., 2021). Despite the promising results obtained during in vivo research, several studies have revealed inconsistencies regarding the antioxidant effect of metformin. The study conducted by Sakellakis et al. underscored that metformin exhibits a characteristic tendency to modulate oxidative phosphorylation (OXPHOS) with the compound’s clinical relevance being widely recognized. Nonetheless, the therapeutic efficacy of metformin in OXPHOS inhibition for cancer patients remains enigmatic. The existing body of evidence indicates that metformin, when administered at therapeutic doses, maintains its plasma concentration within the micromolar range. Although isolated mitochondria necessitate millimolar concentrations for the inhibition of Complex I activity, there exists no substantiated proof supporting the mitochondrial accumulation of metformin. Metformin exerts a subtle impact on the adenosine diphosphate to adenosine triphosphate ratio, culminating in the activation of AMP-activated protein kinase, thereby fostering the activation of ATP-generating catabolic pathways and restoration of cellular energy homeostasis. The metformin’s value as an OXPHOS inhibitor for cancer treatment remains a subject of contention, and prudence is advisable in its utilization for this purpose (Sakellakis, 2023). Thus, molecular alterations under metformin intervention have not clearly demonstrated antioxidant properties. Although multiple reports provide evidence that oxidative stress markers unequivocally decrease in metformin-treated patients, the molecular targets have not been comprehensively determined. Nonetheless, several studies have provided evidence supporting metformin’s involvement in reducing oxidative stress in various cellular contexts. Metformin intervention has been shown to increase the concentrations of mitochondrial complex proteins and glucagon, along with glycerol levels. Conversely, it leads to a decrease in the generation of ROS and levels of hsCRP, and advanced oxidation protein products (AOPP). These findings collectively suggest that metformin has antioxidative effects that extend beyond the modulation of ROS generation. Metformin’s ability to enhance mitochondrial complex proteins and influence various biomarkers related to oxidative stress reflects its potential in managing oxidative status in different physiological conditions. However, further research is needed to comprehensively understand the underlying mechanisms and the extent of metformin’s antioxidative impact in various disease states and patient populations (Abolarin and Schauer, 2024). Hence, metformin is a potential target that protects cells from mitochondrial injury, increases oxidative stress, and attenuates inflammation (Ghavimi et al., 2018). Given the fact that metformin is characterized by pleiotropic properties, including the ability to increase antioxidant ability, it is a promising candidate for preventing many diseases.

Since metformin intervention is safe and well-tolerated among patients, determining the most effective dose in terms of beneficial effects and disease prevention is a significant challenge (Chang et al., 2018). However, determining clinically beneficial doses of metformin is challenging due to the unknown portal vein and liver concentrations of metformin following oral ingestion in humans (Lamoia and Shulman, 2021). Furthermore, since metformin is excreted by the kidneys, patients with eGFR <30 mL/min/1.73 m2 should not receive metformin due to the risk of metformin-associated lactic acidosis (MALA) (Bakris and Molitch, 2016). Additionally, metformin intervention has been associated with vitamin B12 deficiency, so patients at particular risk for this vitamin deficiency should be supplemented with multivitamins to protect against deficiency (Kim et al., 2019).

7 Limitation of metformin use

Metformin, as a popular drug used in the treatment of T2DM, has its application and benefits in improving glycemic control and metabolism in many patients. However, there are certain patient groups and circumstances in which metformin may be inappropriate or require special caution in use. The first group of patients for whom metformin may be inappropriate is individuals with specific kidney conditions (Chen et al., 2013). Since metformin is primarily eliminated through the kidneys, patients with kidney impairment, especially in advanced stages, may be more susceptible to increased drug accumulation and potential adverse effects. In such cases, adjusting the metformin dose or avoiding its use altogether is necessary. Additionally, patients with advanced liver conditions should also avoid metformin or exercise extra caution. The liver plays a significant role in metformin metabolism, and liver dysfunction may lead to drug accumulation and potential side effects. In cases of advance cardiovascular diseases and heart failure, caution is also required in metformin use. Some clinical studies suggest that metformin may have both favorable and unfavorable effects on the cardiovascular system (Graham et al., 2011; Polverino et al., 2021; Sakouhi et al., 2023). Despite these limitations, metformin remains a safe and effective drug for a large number of patients with T2DM, where clinical studies confirm its benefits in various diseases.

8 Conclusion

The investigation of metformin as an antioxidant intervention has yielded promising outcomes in various studies both in vitro and in vivo. Metformin demonstrates antioxidative effects through diverse molecular pathways, including SIRT3 and AMPK pathway activation, restoration of paraoxonase activity, and downregulation of NADPH oxidase expression. These mechanisms collectively contribute to a decrease in reactive oxygen species production and an enhancement of oxidative stress status across different cellular contexts and disease models. However, it is crucial to acknowledge the variability in reported results. While some studies highlight metformin’s antioxidative properties, others indicate increased ROS production or decreased antioxidative enzyme activities. Such discrepancies may stem from differences in study design, patient characteristics, and specific oxidative stress context. Moreover, the effectiveness of metformin as an antioxidant intervention is influenced by factors such as dosage, treatment duration, and underlying medical conditions. Patients with T2DM, metabolic syndrome, or certain kidney or liver impairments may exhibit varied responses to metformin’s antioxidative effects. Despite these complexities, metformin remains a widely used and well-tolerated drug for managing T2DM, with potential benefits extending beyond glycemic control. Its role as an antioxidant intervention, particularly in diseases like cancer prevention and aging-related conditions, is actively researched. To comprehensively understand and harness metformin’s antioxidative potential, additional multicenter clinical trials involving diverse patient populations and varied medical contexts are essential. Long-term studies investigating its impact on cardiovascular health, cancer risk reduction, and other oxidative stress-related conditions will significantly contribute to determining its clinical utility as an antioxidant intervention.

Funding Statement

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was funded by internal financing of Medical University of Bialystok.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding authors.

Author contributions

AB: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Writing–original draft, Writing–review and editing. IS: Data curation, Investigation, Writing–original draft. AK: Software, Supervision, Writing–review and editing. AA: Conceptualization, Formal Analysis, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing–review and editing.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  1. Abolarin J., Schauer I. (2024). Title: effect of metformin on vascular and mitochondrial function in type 1 diabetes short title: metformin and cardiovascular function in T1D. [Google Scholar]
  2. Adamska A., Tomczuk-Bobik P., Popławska-Kita A. B., Siewko K., Buczyńska A., Szumowski P., et al. (2021). Assessment of different markers of ovarian reserve in women with papillary thyroid cancer treated with radioactive iodine. Endocr. Connect. 10, 1283–1290. 10.1530/EC-21-0187 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Adeshara K. A., Bangar N. S., Doshi P. R., Diwan A., Tupe R. S. (2020). Action of metformin therapy against advanced glycation, oxidative stress and inflammation in type 2 diabetes patients: 3 Months follow-up study. Diabetes Metabolic Syndrome Clin. Res. Rev. 14, 1449–1458. 10.1016/j.dsx.2020.07.036 [DOI] [PubMed] [Google Scholar]
  4. Akinci B., Yener S., Bengi G., Yesil S. (2008). Alterations of coagulation in metformin intoxication. Horm. (Athens) 7, 325–329. 10.14310/HORM.2002.1214 [DOI] [PubMed] [Google Scholar]
  5. An H., Wei R., Ke J., Yang J., Liu Y., Wang X., et al. (2016). Metformin attenuates fluctuating glucose-induced endothelial dysfunction through enhancing GTPCH1-mediated ENOS recoupling and inhibiting NADPH oxidase. J. Diabetes Complicat. 30, 1017–1024. 10.1016/J.JDIACOMP.2016.04.018 [DOI] [PubMed] [Google Scholar]
  6. An J., Pei X., Zang Z., Zhou Z., Hu J., Zheng X., et al. (2017). Metformin inhibits proliferation and growth hormone secretion of GH3 pituitary adenoma cells. Oncotarget 8, 37538–37549. 10.18632/ONCOTARGET.16556 [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Andrzejewski S., Gravel S.-P., Pollak M., St-Pierre J. (2014). Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer Metab. 2, 12. 10.1186/2049-3002-2-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Anedda A., Rial E., González-Barroso M. M. (2008). Metformin induces oxidative stress in white adipocytes and raises uncoupling protein 2 levels. J. Endocrinol. 199, 33–40. 10.1677/JOE-08-0278 [DOI] [PubMed] [Google Scholar]
  9. Bahne E., Sun E. W. L., Young R. L., Hansen M., Sonne D. P., Hansen J. S., et al. (2018). Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes. JCI Insight 3, e93936. 10.1172/JCI.INSIGHT.93936 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Bai B., Chen H. (2021). Metformin: a novel weapon against inflammation. Front. Pharmacol. 12, 15. 10.3389/fphar.2021.622262 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Bakris G. L., Molitch M. E. (2016). Should restrictions Be relaxed for metformin use in chronic kidney disease? Yes, they should Be relaxed! What’s the fuss? Diabetes Care 39, 1287–1291. 10.2337/DC15-2534 [DOI] [PubMed] [Google Scholar]
  12. Bharath L. P., Nikolajczyk B. S. (2021). The intersection of metformin and inflammation. Am. J. Physiol. Cell Physiol. 320, C873–C879. 10.1152/AJPCELL.00604.2020 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Blacker T. S., Duchen M. R. (2016). Investigating mitochondrial redox state using NADH and NADPH autofluorescence. Free Radic. Biol. Med. 100, 53–65. 10.1016/J.FREERADBIOMED.2016.08.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Buczyńska A., Sidorkiewicz I., Kościuszko M., Adamska A., Siewko K., Dzięcioł J., et al. (2023b). The relationship between oxidative status and radioiodine treatment qualification among papillary thyroid cancer patients. Cancers 15, 2436. 10.3390/CANCERS15092436 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Buczyńska A., Sidorkiewicz I., Kościuszko M., Adamska A., Siewko K., Dzięcioł J., et al. (2023a). Clinical significance of oxidative stress markers as angioinvasion and metastasis indicators in papillary thyroid cancer. Nature 13. 10.1038/s41598-023-40898-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Buczyńska A., Sidorkiewicz I., Krętowski A. J., Zbucka-Krętowska M. (2023c). The role of oxidative stress in trisomy 21 phenotype. Cell Mol. Neurobiol. 43, 3943–3963. 10.1007/S10571-023-01417-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Buczyńska A., Sidorkiewicz I., Krętowski A. J., Zbucka-Krętowska M., Adamska A. (2022). Metformin intervention-A panacea for cancer treatment? Cancers (Basel) 14, 1336. 10.3390/CANCERS14051336 [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Buczyńska A., Sidorkiewicz I., Ławicki S., Krętowski A., Zbucka-Krętowska M. (2020). The significance of apolipoprotein E measurement in the screening of fetal down syndrome. J. Clin. Med. 9, 3995. 10.3390/jcm9123995 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Buczyńska A., Sidorkiewicz I., Ławicki S., Krętowski A. J., Zbucka-Krętowska M. (2021b). Prenatal screening of trisomy 21: could oxidative stress markers play a role? J. Clin. Med. 10, 2382. 10.3390/jcm10112382 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Buczyńska A., Sidorkiewicz I., Rogucki M., Siewko K., Adamska A., Kościuszko M., et al. (2021a). Oxidative stress and radioiodine treatment of differentiated thyroid cancer, 11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Bułdak Ł., Łabuzek K., Bułdak R. J., Machnik G., Bołdys A., Basiak M., et al. (2016). Metformin reduces the expression of NADPH oxidase and increases the expression of antioxidative enzymes in human monocytes/macrophages cultured in vitro . Exp. Ther. Med. 11, 1095–1103. 10.3892/ETM.2016.2977 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  22. Chakraborty A., Chowdhury S., Bhattacharyya M. (2011). Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabetes Res. Clin. Pract. 93, 56–62. 10.1016/J.DIABRES.2010.11.030 [DOI] [PubMed] [Google Scholar]
  23. Chang Y. T., Tsai H. L., Kung Y. T., Yeh Y. S., Huang C. W., Ma C. J., et al. (2018). Dose-dependent relationship between metformin and colorectal cancer occurrence among patients with type 2 diabetes-A nationwide cohort study. Transl. Oncol. 11, 535–541. 10.1016/J.TRANON.2018.02.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Chen S., Zhou J., Xi M., Jia Y., Wong Y., Zhao J., et al. (2013). Pharmacogenetic variation and metformin response. Curr. Drug Metab. 14, 1070–1082. 10.2174/1389200214666131211153933 [DOI] [PubMed] [Google Scholar]
  25. Cheng G., Lanza-Jacoby S. (2015). Metformin decreases growth of pancreatic cancer cells by decreasing reactive oxygen species: role of NOX4. Biochem. Biophys. Res. Commun. 465, 41–46. 10.1016/J.BBRC.2015.07.118 [DOI] [PubMed] [Google Scholar]
  26. Clarke B. F., Duncan L. J. (1968). Comparison of chlorpropamide and metformin treatment on weight and blood-glucose response of uncontrolled obese diabetics. Lancet 291, 123–126. 10.1016/S0140-6736(68)92726-8 [DOI] [PubMed] [Google Scholar]
  27. Corcoran C., Jacobs T. F. (2021). Metformin. Encyclopedia of biomedical gerontology, 424–432. 10.1016/B978-0-12-801238-3.62141-4 [DOI] [Google Scholar]
  28. Dare A., Channa M. L., Nadar A. (2021). L-ergothioneine and its combination with metformin attenuates renal dysfunction in type-2 diabetic rat model by activating Nrf2 antioxidant pathway. Biomed. Pharmacother. 141, 111921. 10.1016/J.BIOPHA.2021.111921 [DOI] [PubMed] [Google Scholar]
  29. Diaz-Morales N., Rovira-Llopis S., Bañuls C., Lopez-Domenech S., Escribano-Lopez I., Veses S., et al. (2017). Does metformin protect diabetic patients from oxidative stress and leukocyte-endothelium interactions? Antioxid. Redox Signal 27, 1439–1445. 10.1089/ARS.2017.7122 [DOI] [PubMed] [Google Scholar]
  30. Diniz Vilela D., Gomes Peixoto L., Teixeira R. R., Belele Baptista N., Carvalho Caixeta D., Vieira De Souza A., et al. (2016). The role of metformin in controlling oxidative stress in muscle of diabetic rats. Oxid. Med. Cell Longev. 2016, 6978625. 10.1155/2016/6978625 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Dutta K., Podolin D. A., Davidson M. B., Davidoff A. J. (2001). Cardiomyocyte dysfunction in sucrose-fed rats is associated with insulin resistance. Diabetes 50, 1186–1192. 10.2337/DIABETES.50.5.1186 [DOI] [PubMed] [Google Scholar]
  32. Esteghamati A., Eskandari D., Mirmiranpour H., Noshad S., Mousavizadeh M., Hedayati M., et al. (2013). Effects of metformin on markers of oxidative stress and antioxidant reserve in patients with newly diagnosed type 2 diabetes: a randomized clinical trial. Clin. Nutr. 32, 179–185. 10.1016/J.CLNU.2012.08.006 [DOI] [PubMed] [Google Scholar]
  33. Foretz M., Guigas B., Viollet B. (2023). Metformin: update on mechanisms of action and repurposing potential. Nat. Rev. Endocrinol. 19, 460–476. 10.1038/S41574-023-00833-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Forman H. J., Zhang H. (2021). Targeting oxidative stress in disease: promise and limitations of antioxidant therapy. Nat. Rev. Drug Discov. 20, 689–709. 10.1038/s41573-021-00233-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Genazzani A. D., Strucchi C., Luisi M., Casarosa E., Lanzoni C., Baraldi E., et al. (2009). Metformin administration modulates neurosteroids secretion in non-obese amenorrhoic patients with polycystic ovary syndrome. Gynecol. Endocrinol. 22, 36–43. 10.1080/09513590500476164 [DOI] [PubMed] [Google Scholar]
  36. Ghavimi H., Sheidaei S., Vaez H., Zolali E., Asgharian P., Hamishehkar H. (2018). Metformin-attenuated sepsis-induced oxidative damages: a novel role for metformin. Iran. J. Basic Med. Sci. 21, 469–475. 10.22038/IJBMS.2018.24610.6126 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Graham G. G., Punt J., Arora M., Day R. O., Doogue M. P., Duong J. K., et al. (2011). Clinical pharmacokinetics of metformin. Clin. Pharmacokinet. 50, 81–98. 10.2165/11534750-000000000-00000 [DOI] [PubMed] [Google Scholar]
  38. He L., Sabet A., Djedjos S., Miller R., Sun X., Hussain M. A., et al. (2009). Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 137, 635–646. 10.1016/J.CELL.2009.03.016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Hirsch H. A., Iliopoulos D., Struhl K. (2013). Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc. Natl. Acad. Sci. U. S. A. 110, 972–977. 10.1073/PNAS.1221055110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Hou X., Song J., Li X. N., Zhang L., Wang X. L., Chen L., et al. (2010). Metformin reduces intracellular reactive oxygen species levels by upregulating expression of the antioxidant thioredoxin via the AMPK-FOXO3 pathway. Biochem. Biophys. Res. Commun. 396, 199–205. 10.1016/J.BBRC.2010.04.017 [DOI] [PubMed] [Google Scholar]
  41. Javadipour M., Rezaei M., Keshtzar E., Khodayar M. J. (2019). Metformin in contrast to berberine reversed arsenic-induced oxidative stress in mitochondria from rat pancreas probably via sirt3-dependent pathway. J. Biochem. Mol. Toxicol. 33, e22368. 10.1002/JBT.22368 [DOI] [PubMed] [Google Scholar]
  42. Jia D., Li Z. W., Zhou X., Gao Y., Feng Y., Ma M., et al. (2019). A novel berberine-metformin hybrid compound exerts therapeutic effects on obese type 2 diabetic rats. Clin. Exp. Pharmacol. Physiol. 46, 533–544. 10.1111/1440-1681.13085 [DOI] [PubMed] [Google Scholar]
  43. Johanns M., Lai Y. C., Hsu M. F., Jacobs R., Vertommen D., Van Sande J., et al. (2016). AMPK antagonizes hepatic glucagon-stimulated cyclic AMP signalling via phosphorylation-induced activation of cyclic nucleotide phosphodiesterase 4B. Nat. Commun. 7, 10856. 10.1038/NCOMMS10856 [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Kefas B. A., Cai Y., Kerckhofs K., Ling Z., Martens G., Heimberg H., et al. (2004). Metformin-induced stimulation of AMP-activated protein kinase in beta-cells impairs their glucose responsiveness and can lead to apoptosis. Biochem. Pharmacol. 68, 409–416. 10.1016/j.bcp.2004.04.003 [DOI] [PubMed] [Google Scholar]
  45. Kim J., Ahn C. W., Fang S., Lee H. S., Park J. S. (2019). Association between metformin dose and vitamin B12 deficiency in patients with type 2 diabetes. Medicine 98, e17918. 10.1097/MD.0000000000017918 [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Klein J., Westphal S., Kraus D., Meier B., Perwitz N., Ott V., et al. (2004). Metformin inhibits leptin secretion via a mitogen-activated protein kinase signalling pathway in Brown adipocytes. J. Endocrinol. 183, 299–307. 10.1677/JOE.1.05646 [DOI] [PubMed] [Google Scholar]
  47. Kościuszko M., Buczyńska A., Krętowski A. J., Popławska-Kita A. (2023). Could oxidative stress play a role in the development and clinical management of differentiated thyroid cancer? Cancers (Basel) 15, 3182. 10.3390/CANCERS15123182 [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Lai Y. C., Tabima D. M., Dube J. J., Hughan K. S., Vanderpool R. R., Goncharov D. A., et al. (2016). SIRT3-AMP-Activated protein kinase activation by nitrite and metformin improves hyperglycemia and normalizes pulmonary hypertension associated with heart failure with preserved ejection fraction. Circulation 133, 717–731. 10.1161/CIRCULATIONAHA.115.018935 [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Lamoia T. E., Shulman G. I. (2021). Cellular and molecular mechanisms of metformin action. Endocr. Rev. 42, 77–96. 10.1210/ENDREV/BNAA023 [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Liu W., Wang Y., Luo J., Liu M., Luo Z. (2021). Pleiotropic effects of metformin on the antitumor efficiency of immune checkpoint inhibitors. Front. Immunol. 11, 3724. 10.3389/fimmu.2020.586760 [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Luengo A., Sullivan L. B., Heiden V. G. V. (2014). Understanding the complex-I-ty of metformin action: limiting mitochondrial respiration to improve cancer therapy. BMC Biol. 12, 82. 10.1186/S12915-014-0082-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Lv Z., Guo Y. (2020). Metformin and its benefits for various diseases. Front. Endocrinol. (Lausanne) 11, 191. 10.3389/FENDO.2020.00191 [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Madiraju A. K., Erion D. M., Rahimi Y., Zhang X. M., Braddock D. T., Albright R. A., et al. (2014). Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510, 542–546. 10.1038/NATURE13270 [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Madiraju A. K., Qiu Y., Perry R. J., Rahimi Y., Zhang X. M., Zhang D., et al. (2018). Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo . Nat. Med. 24, 1384–1394. 10.1038/S41591-018-0125-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Mallik R., Chowdhury T. A. (2018). Metformin in cancer. Diabetes Res. Clin. Pract. 143, 409–419. 10.1016/J.DIABRES.2018.05.023 [DOI] [PubMed] [Google Scholar]
  56. Marc F., Bruno G., Luc B., Michael P., Benoit V., Pollak M., et al. (2014). Metformin: from mechanisms of action to therapies. Cell Metab. 20, 953–966. 10.1016/J.CMET.2014.09.018 [DOI] [PubMed] [Google Scholar]
  57. McCreight L. J., Bailey C. J., Pearson E. R. (2016). Metformin and the gastrointestinal tract. Diabetologia 59, 426–435. 10.1007/S00125-015-3844-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Meng X., Xu S., Chen G., Derwahl M., Liu C. (2017). Metformin and thyroid disease. J. Endocrinol. 233, R43-R51. –R51. 10.1530/JOE-16-0450 [DOI] [PubMed] [Google Scholar]
  59. Meyer M. J., Tuerkova A., Römer S., Wenzel C., Seitz T., Gaedcke J., et al. (2020). Differences in metformin and thiamine uptake between human and mouse organic cation transporter 1: structural determinants and potential consequences for intrahepatic concentrations. Drug Metab. Dispos. 48, 1380–1392. 10.1124/DMD.120.000170 [DOI] [PubMed] [Google Scholar]
  60. Miller R. A., Chu Q., Xie J., Foretz M., Viollet B., Birnbaum M. J. (2013). Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 494, 256–260. 10.1038/NATURE11808 [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Mirmiranpour H., Mousavizadeh M., Noshad S., Ghavami M., Ebadi M., Ghasemiesfe M., et al. (2013). Comparative effects of pioglitazone and metformin on oxidative stress markers in newly diagnosed type 2 diabetes patients: a randomized clinical trial. J. Diabetes Complicat. 27, 501–507. 10.1016/J.JDIACOMP.2013.05.006 [DOI] [PubMed] [Google Scholar]
  62. Mulherin A. J., Oh A. H., Kim H., Grieco A., Lauffer L. M., Brubaker P. L. (2011). Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology 152, 4610–4619. 10.1210/EN.2011-1485 [DOI] [PubMed] [Google Scholar]
  63. Musi N., Hirshman M. F., Nygren J., Svanfeldt M., Bavenholm P., Rooyackers O., et al. (2002). Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51, 2074–2081. 10.2337/DIABETES.51.7.2074 [DOI] [PubMed] [Google Scholar]
  64. Ouslimani N., Peynet J., Bonnefont-Rousselot D., Thérond P., Legrand A., Beaudeux J. L. (2005). Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells. Metabolism 54, 829–834. 10.1016/J.METABOL.2005.01.029 [DOI] [PubMed] [Google Scholar]
  65. Park D. (2019). Metformin induces oxidative stress-mediated apoptosis without the blockade of glycolysis in H4IIE hepatocellular carcinoma cells. Biol. Pharm. Bull. 42, 2002–2008. 10.1248/BPB.B19-00474 [DOI] [PubMed] [Google Scholar]
  66. Pavlovic D., Kocić R., Kocić G., Jevtović T., Radenković S., Mikić D., et al. (2000). Effect of four-week metformin treatment on plasma and erythrocyte antioxidative defense enzymes in newly diagnosed obese patients with type 2 diabetes. Diabetes Obes. Metab. 2, 251–256. 10.1046/J.1463-1326.2000.00089.X [DOI] [PubMed] [Google Scholar]
  67. Polverino F., Wu T. D., Rojas-Quintero J., Wang X., Mayo J., Tomchaney M., et al. (2021). Metformin: experimental and clinical evidence for a potential role in emphysema treatment. Am. J. Respir. Crit. Care Med. 204, 651–666. 10.1164/RCCM.202012-4510OC [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Roxo D. F., Arcaro C. A., Gutierres V. O., Costa M. C., Oliveira J. O., Lima T. F. O., et al. (2019). Curcumin combined with metformin decreases glycemia and dyslipidemia, and increases paraoxonase activity in diabetic rats. Diabetol. Metab. Syndr. 11, 33. 10.1186/S13098-019-0431-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Sakellakis M. (2023). Why metformin should not Be used as an oxidative phosphorylation inhibitor in cancer patients. Chemotherapy 68, 185–189. 10.1159/000531606 [DOI] [PubMed] [Google Scholar]
  70. Sakouhi M., Matmour D., Belakhdar K., Kraroubi A. (2023). Cross-sectional study on adverse effects of metformin hydrochloride on 130 patients type 2 diabetic admitted to medical center and diabetes home of sidi bel-abbès. Ann. Pharm. Fr. 81, 684–695. 10.1016/J.PHARMA.2022.11.013 [DOI] [PubMed] [Google Scholar]
  71. Salvatore T., Pafundi P. C., Galiero R., Rinaldi L., Caturano A., Vetrano E., et al. (2021). Can metformin exert as an active drug on endothelial dysfunction in diabetic subjects? Biomedicines 9, 3. 10.3390/BIOMEDICINES9010003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Samsuri N. A. B., Leech M., Marignol L. (2017). Metformin and improved treatment outcomes in radiation therapy - a review. Cancer Treat. Rev. 55, 150–162. 10.1016/J.CTRV.2017.03.005 [DOI] [PubMed] [Google Scholar]
  73. Schiavo J. H.PROSPERO. (2019). PROSPERO: an international register of systematic review protocols. Med. Ref. Serv. Q. 38, 171–180. 10.1080/02763869.2019.1588072 [DOI] [PubMed] [Google Scholar]
  74. Shao R., Li X., Feng Y., Lin J. F., Billig H. (2014). Direct effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma. J. Exp. Clin. Cancer Res. 33, 41. 10.1186/1756-9966-33-41 [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Sirmans S. M., Pate K. A. (2014). Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin. Epidemiol. 6, 1–13. 10.2147/CLEP.S37559 [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Triggle C. R., Mohammed I., Bshesh K., Marei I., Ye K., Ding H., et al. (2022). Metformin: is it a drug for all reasons and diseases? Metabolism 133, 155223. 10.1016/J.METABOL.2022.155223 [DOI] [PubMed] [Google Scholar]
  77. Vancura A., Bu P., Bhagwat M., Zeng J., Vancurova I. (2018). Metformin as an anticancer agent. Trends Pharmacol. Sci. 39, 867–878. 10.1016/J.TIPS.2018.07.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. van Stee M. F., de Graaf A. A., Groen A. K., Stee M.F. van, Graaf A.A. de, Groen A. K., et al. (2018). Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy. Cardiovasc Diabetol. 17, 94. 10.1186/S12933-018-0738-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Vause T. D. R., Cheung A. P., Cheung A. P., Sierra S., Claman P., Graham J., et al. (2010). Ovulation induction in polycystic ovary syndrome. J. Obstet. Gynaecol. Can. 32, 495–502. 10.1016/S1701-2163(16)34504-2 [DOI] [PubMed] [Google Scholar]
  80. Viollet B., Guigas B., Sanz Garcia N., Leclerc J., Foretz M., Andreelli F. (2012). Cellular and molecular mechanisms of metformin: an overview. Clin. Sci. (Lond) 122, 253–270. 10.1042/CS20110386 [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Zhang F., Sun W., Chen J., Jiang L., Yang P., Huang Y., et al. (2018). SREBP-2, a new target of metformin? Drug Des. Devel Ther. 12, 4163–4170. 10.2147/DDDT.S190094 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding authors.

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES